Curt LaBelle, M.D. Appointed to Revelation Biosciences, Inc. Board of Directors

MENLO PARK, Calif.--(BUSINESS WIRE)--Revelation Biosciences Inc. (Revelation), a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today the appointment of Curt LaBelle, M.D. to the Company’s Board of Directors (Board).

“I am very impressed with all that the Revelation team accomplished in 2020,” said Dr. LaBelle. “I look forward to using my expertise to help the company as it advances forward in development.”

"We extend our warmest welcome to Dr. LaBelle and are delighted to add another talented leader to our Board,” said James Rolke, Chief Executive Officer of Revelation. “His extensive knowledge of the biotech industry and his expertise will be highly valuable to the Company as we continue to execute on our goals of bringing REVTx-99 and REVDx-501 to patients.”

Dr. LaBelle has been investing in and working with life science companies for over 20 years. Since 2015, he has been President of the Global Health Investment Fund (GHIF). GHIF is a pioneering impact fund with a proven record of generating attractive financial returns and tangible impact. The fund works to facilitate access to therapeutics and diagnostics among low-income populations. Dr. LaBelle also works with the AXA Prime Impact Fund and serves as a Board member for Alydia Health, Atomo Diagnostics (ASX: AT1), Atticus Medical, Eyenovia (Nasdaq: EYEN), and Z Optics. Dr. LaBelle received his M.D. and M.B.A from Columbia University.

For more information on Revelation, please visit www.RevBiosciences.com.

About Revelation Biosciences Inc.

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on the development of immunologic‑based therapies for the prevention and treatment of disease. The Company has several product candidates in development. REVTx‑99, the lead therapeutic candidate, is an intranasal immunomodulator for the early treatment of SARS‑CoV‑2 infection. An expansion of REVTx‑99 therapeutic indications is planned, targeting early treatment and prevention of respiratory viral infection such as influenza A or B, parainfluenza, and respiratory syncytial virus. REVTx‑200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx‑200 is based on the same technology used in REVTx-99. In addition to the Company’s therapeutic pipeline, Revelation is also developing REVDx‑501, a rapid point of care diagnostic that can be used to detect any respiratory viral infection regardless of virus type without the need for specialized instrumentation. For more information on Revelation, please visit www.RevBiosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. The Company undertakes no obligations to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by applicable laws. These risks include, but are not limited to, risks relating to: the timing and success of future development activities for REVTx-99 and expanded indications, REVTx-200, REVDx-501, or any other product candidates; potential indications for which our product candidates may be developed; the potential impact that COVID-19 may have on us, our suppliers, vendors, regulatory agencies, our employees, and the global economy as a whole; and the expected duration over which the Company’s balance will fund us.